SCHEMBL2850336

SCHEMBL2850336

NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1

nearest known ligand 0.77

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.74
TSHR P16473 1/20 0.73
RECQL P46063 1/20 0.73
ALDH1A1 P00352 1/20 0.67
LMNA P02545 1/20 0.67
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
MAPK1 P28482 1/20 0.61
NPC1 O15118 1/20 0.61
AKR1C3 P42330 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28283475 0.88 TSHR (0.77) GAATSHRRECQLALDH1A1LMNA
SCHEMBL30005696 0.87 MAPT (0.76) GAATSHRRECQLALDH1A1KMT2A
SCHEMBL34841 0.87 MAPT (0.76) GAATSHRRECQLALDH1A1KMT2A
SCHEMBL5039031 0.87 GAA (0.97) GAATSHRALDH1A1LMNAAKR1C3
SCHEMBL7321050 0.86 KMT2A (0.80) TSHRRECQLALDH1A1KMT2AMEN1
SCHEMBL15773014 0.86 TSHR (0.73) GAATSHRRECQLALDH1A1KMT2A
SCHEMBL14507610 0.85 GAA (1.00) GAATSHRALDH1A1LMNAKMT2A
SCHEMBL14696868 0.85 MAPK1 (0.71) GAATSHRRECQLALDH1A1KMT2A
SCHEMBL2852725 0.83 GAA (0.74) GAATSHRALDH1A1LMNAKMT2A
SCHEMBL2851156 0.83 GAA (0.74) GAATSHRRECQLALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103889953-B Sulfamoylbenzamide derivatives as antiviral agents against hepatitis B virus infection 巴鲁﹒S﹒布隆伯格研究所 2016-06-08 CN claimed
CN-103889953-A Sulfamoylbenzamide Derivatives as Antiviral Agents Against Hepatitis B Virus Infection INST HEPATITIS & VIRUS RES 2014-06-25 CN claimed
US-20100234377-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2010-09-16 US claimed
EP-2150532-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE Evotec AG (DE) 2010-02-10 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-2094082-A2 ACTIVATORS OF LATERAL ROOT FORMATION VIB VZW (BE) 2009-09-02 EP claimed
WO-2008122787-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2008-10-16 WO claimed
WO-2008062035-A2 ACTIVATORS OF LATERAL ROOT FORMATION VIB VZW (BE) 2008-05-29 WO claimed
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP claimed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP claimed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO claimed
WO-2025003988-A1 NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 동화약품주식회사 2025-01-02 WO disclosed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-20100234377-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2010-09-16 US disclosed
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234377-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE HPGDS, PTGDR, PTGIS GAA 1250/4885TSHR 3399/4885RECQL 812/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 GAA 4722/4885TSHR 3666/4885RECQL 3836/4885
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT GAA 1396/4885TSHR 3378/4885RECQL 1052/4885
US-10752640-B2 Compounds active towards bromodomains BRD4, BRD3, BRDT GAA 1396/4885TSHR 3378/4885RECQL 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.